- Conditions
- Brain Cancer
- Interventions
- Afatinib
- Drug
- Lead sponsor
- Santosh Kesari
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Santa Monica, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 77
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
- Interventions
- CNSide
- Device
- Lead sponsor
- Biocept, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Stanford, California • Chicago, Illinois • Dallas, Texas + 1 more
- Conditions
- Neoplastic Meningitis, Solid Tumor, Lymphoma, Leukemia, Brain Tumor
- Interventions
- RTA 744
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer Female, Leptomeningeal Metastases
- Interventions
- HER2 BATs
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Leptomeningeal Cancer
- Interventions
- Neurological Assessment
- Other
- Lead sponsor
- University of Zurich
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Central Nervous System Tumors, Brain Tumors
- Interventions
- Gallium-67 Citrate (Ga-67), In-111 DTPA (In-111 pentetate)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Leptomeningeal Metastasis
- Interventions
- OncoCEE
- Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma
- Interventions
- iodine I 131 monoclonal antibody 3F8
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Sapanisertib, Telaglenastat Hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 2 more
- Conditions
- Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
- Interventions
- Dendritic Cell Vaccine
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
- Interventions
- Mirdametinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 24 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 11
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
- Interventions
- Radiation Therapy, Pertuzumab, Trastuzumab
- Radiation · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Evanston, Illinois
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma, Metastatic Cancer, Retinoblastoma, Sarcoma
- Interventions
- busulfan
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 8
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more
- Conditions
- Metastatic Cancer
- Interventions
- monoclonal antibody Me1-14 F(ab')2
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2004
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- LMB-7 immunotoxin
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma
- Interventions
- Trastuzumab deruxtecan
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma, Ovarian Cancer
- Interventions
- melphalan
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2001
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- ALK-positive Non-small Cell Lung Cancer
- Interventions
- Ceritinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Stanford, California • South Bend, Indiana + 4 more
- Conditions
- Leptomeningeal Metastasis
- Interventions
- 186RNL
- Drug
- Lead sponsor
- Plus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Manhasset, New York • New York, New York + 3 more
- Conditions
- Neoplastic Meningitis
- Interventions
- DepoCyt, Temozolomide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumor, High-grade Glioma, Leptomeningeal Metastasis
- Interventions
- Azeliragon, CSI
- Drug · Procedure
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Central Nervous System Neoplasms, Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Pediatric, Brain Tumor Adult, Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma, Adult, Medulloblastoma Recurrent, Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma, Leptomeningeal Disease
- Interventions
- B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Robbie Majzner
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts